Richard A. Larson to International Agencies
This is a "connection" page, showing publications Richard A. Larson has written about International Agencies.
Connection Strength
0.051
-
Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study. Leukemia. 2013 Jan; 27(1):107-12.
Score: 0.027
-
Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy. Leukemia. 2010 Jul; 24(7):1299-301.
Score: 0.024